Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02186600 · ClinicalTrials.gov registry record · Phase 3
Heartland Osteoporosis Prevention Study
A Phase 3 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 3
- Development phase
- 276
- Enrollment target
NCT02186600 is a Phase 3 study that has completed, run by University of Nebraska. The registered enrollment target is 276 participants.
The verdict
NCT02186600, a Phase 3 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 276 participants
- Enrollment target
Study Summary
The purpose of this study is to identify the best way to prevent bone loss in the first years after menopause. The HOPS study will compare bone loss at 12 months in women: 1) who take calcium and vitamin D only; 2) who take calcium and vitamin D plus the medication "risedronate"; or 3) who take calcium and vitamin D plus participate in bone-loading exercises. Our central hypothesis is that improvements in bone health will be greater in women randomized to bone-loading exercises with calcium and vitamin D compared to women who take calcium and vitamin D only or women who take calcium and vitamin D plus risedronate.
Interventions
- DRUG Risedronate
- DRUG Vitamin D3
- DRUG Calcium Carbonate
- BEHAVIORAL Bone-loading exercises
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2015-02-01 |
| Est. Completion | 2019-06-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02186600
The ClinicalTrials.gov registry entry for NCT02186600 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Risedronate is the first listed.
NCT02186600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02186600 about?
NCT02186600 is a clinical study titled "Heartland Osteoporosis Prevention Study". The purpose of this study is to identify the best way to prevent bone loss in the first years after menopause. The HOPS study will compare bone loss at 12 months in women: 1) who take calcium and vitamin D only; 2) who take calcium and vitamin D plus the medication "risedronate"; or 3) who take calc...
What is the current status of trial NCT02186600?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 276 participants. The study started on 2015-02-01. Estimated completion is 2019-06-01.
What interventions are being tested in trial NCT02186600?
The interventions under investigation include: Risedronate (DRUG), Vitamin D3 (DRUG), Calcium Carbonate (DRUG), Bone-loading exercises (BEHAVIORAL).
Who is sponsoring clinical trial NCT02186600?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.